Spots Global Cancer Trial Database for Olaparib in Treating Patients With Stage IV Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Official Title: Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study

Study ID: NCT02677038

Conditions

Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions

Olaparib

Study Description

Brief Summary: This phase II trial studies how well olaparib works in treating patients with stage IV pancreatic cancer. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the efficacy of olaparib monotherapy in stage IV pancreatic ductal adenocarcinoma (PDAC) with breast cancer, early onset (BRCA)ness. SECONDARY OBJECTIVES: I. To further determine the efficacy of olaparib in the study population. SAFETY OBJECTIVES: I. To assess the safety and tolerability of olaparib. EXPLORATORY OBJECTIVES: I. To identify tissue based biomarkers of defective homologous recombination repair (HRD). OUTLINE: Patients receive olaparib orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 8 weeks thereafter.